Copyright
©The Author(s) 2024.
World J Stem Cells. Feb 26, 2024; 16(2): 70-88
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
No | Trial ID | UC-MSCs administration protocol | Phase | Status | Patients | Age | Follow-up time | Mask | Allocation | Country | ||
Frequency | Dose (cells) | Route | ||||||||||
1 | NCT04062136 | 2 (at days 1 and 8) | 1 × 106/kg | IV | I | Unknown | 10 | 1-6 months | N/A | Open-label | N/A | Vietnam |
2 | NCT02381366 | 1 | Dose A: 1 × 107/kg; dose B: 2 × 107/kg | N/A | I/II | Completed | 12 | 3-14 d | N/A | Open-label | N/A | United States |
3 | NCT03645525 | 1 | 2 × 107/kg | Endobronchial | I/II | Recruiting | 180 | 2-3 wk | N/A | Quadruple-blind | Randomized | China |
4 | NCT03601416 | 1 | Dose A: 1 × 106/kg, dose B: 5 × 106/kg | IV | II | Unknown | 21 | 28 d to 1 yr | N/A | Open-label | Randomized | China |
5 | NCT03558334 | 1 | Dose A: 1 × 106/kg, dose B: 5 × 106/kg | IV | I | Unknown | 12 | 28 d and older | N/A | Open-label | Non-randomized | China |
6 | NCT01207869 | 1 | 3 × 106/kg | Endobronchial | I | Unknown | 10 | 1 wk to 6 months | N/A | Double-blind | Randomized | China |
7 | NCT03873506 | 1 | Dose A: 1 × 106/kg, dose B: 5 × 106/kg | IV | I | Unknown | 30 | 1 months to 5 yr | N/A | Open-label | N/A | China |
8 | NCT03774537 | 1 | Dose A: 1 × 106/kg, dose B: 5 × 106/kg | IV | I/II | Unknown | 20 | 4-14 d | N/A | Open-label | Non-randomized | China |
9 | NCT03631420 | 1 | Dose A: 3 × 106/kg, dose B: 1 × 107/kg, dose C: 3 × 107/kg | N/A | I | Recruiting | 9 | 3-51 d | N/A | Open-label | N/A | China |
10 | NCT01632475 | 1 | Dose A: 1 × 107/kg, dose B: 2 × 107/kg | IV | I | Active, not recruiting | 9 | 4 months to 2 yr | N/A | Open-label | N/A | Korea |
11 | NCT01297205 | 1 | Dose A: 1 × 107/kg, dose B: 2 × 107/kg | IV | I | Completed | 9 | 5-14 d | N/A | Open-label | N/A | Korea |
12 | NCT04003857 | 1 | 1 × 107/kg | IV | II | Recruiting | 60 | 6-60 months | N/A | Triple-blind | Randomized | Korea |
13 | NCT01897987 | 1 | 1 × 107/kg | IV | N/A | Completed | 62 | 7 months | 60 months | Triple-blind | Randomized | Korea |
14 | NCT01828957 | 1 | 1 × 107/kg | IV | II | Completed | 69 | 5-14 d | N/A | Quadruple-blind | Randomized | Korea |
15 | NCT02023788 | 1 | Dose A: 1 × 107/kg, dose B: 2 × 107/kg | IV | I | Completed | 8 | 45-63 months | 5 yr | Open-label | N/A | Korea |
16 | NCT03378063 | 1 | N/A | N/A | I | Withdrawn | 100 | 1-3 months | N/A | Open-label | Non-randomized | China |
17 | NCT03392467 | 1 | N/A | N/A | II | Recruiting | 60 | Up to 13 d | N/A | Quadruple-blind | Randomized | Korea |
18 | NCT04255147 | 1 | Dose A: 1 × 106/kg, dose B: 3 × 106/kg, dose C: 1 × 107/kg | IV | I | Recruiting | 9 | 7-28 d | N/A | Open-label | N/A | Canada |
- Citation: Meng M, Zhang WW, Chen SF, Wang DR, Zhou CH. Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects. World J Stem Cells 2024; 16(2): 70-88
- URL: https://www.wjgnet.com/1948-0210/full/v16/i2/70.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i2.70